{"id":"NCT03430856","sponsor":"Biocon Limited","briefTitle":"Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients","officialTitle":"An Open Label, Multi-center, Randomized, Parallel Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Insulin Tregopil (IN-105) Compared With Insulin Aspart in the Treatment of Patients With Type 2 Diabetes Mellitus on Stable Dose of Metformin and Insulin Glargine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-12-26","primaryCompletion":"2019-02-06","completion":"2019-02-20","firstPosted":"2018-02-13","resultsPosted":"2020-05-15","lastUpdate":"2020-05-15"},"enrollment":143,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin Tregopil","otherNames":["IN-105"]},{"type":"DRUG","name":"Insulin Aspart","otherNames":[]}],"arms":[{"label":"Insulin Tregopil (IN-105) - 45mg","type":"EXPERIMENTAL"},{"label":"Insulin Tregopil (IN-105) - 30mg","type":"EXPERIMENTAL"},{"label":"Insulin Aspart","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open label Phase II/III study to evaluate the efficacy and safety of test drug, Insulin Tregopil (IN-105) compared with Insulin Aspart (IAsp) in Type 2 Diabetes Mellitus patients. on stable dose of Metformin and insulin Glargine. The study will be conducted in 2 parts, Part I and Part II. The study duration will be approximately 37 weeks for Part I and for Part II of the study respectively","primaryOutcome":{"measure":"Change From Baseline in HbA1c at 24 Weeks (Part 1)","timeFrame":"Week 0, Week 24","effectByArm":[{"arm":"Insulin Tregopil (IN-105) - 45mg","deltaMin":8.23,"sd":0.577},{"arm":"Insulin Tregopil (IN-105) - 30mg","deltaMin":8.1,"sd":0.67},{"arm":"Insulin Aspart","deltaMin":8.07,"sd":0.697}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":1,"countries":["India"]},"refs":{"pmids":["36352762"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Gastritis","Pyrexia","Nausea","Pain","Urinary tract infection"]}}